Peter Hecht’s Ironwood spinout fails back-to-back studies on a key drug, crushing shares and triggering cutbacks — but he still sees a path forward
Peter Hecht’s plan to pivot from a mid-stage start at his newly created biotech Cyclerion — spun out of Ironwood — right into late-stage programs on a path to commercialization has run straight into a major setback.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
